Alnylam rises on 1st human data for subcutaneous RNAi drug
This article was originally published in Scrip
Executive Summary
Alnylam Pharmaceuticals traded at an all-time high on 11 July, closing up 15.8% at $43.53 per share after the company revealed positive data from the first-ever human clinical trial for a subcutaneous formulation of one of its gene-silencing therapeutics.